Combining in vitro and in silico approaches to find new drugs targeting the pathological proteins related to the Alzheimer's disease.

Combining in vitro and in silico approaches to find new drugs targeting the pathological proteins related to the Alzheimer's disease. Curr Neuropharmacol. 2017 Oct 30;: Authors: Li H, Wang X, Yu H, Zhu J, Jin H, Wang A, Yang Z Abstract Alzheimer's disease (AD) is a multifactorial and complicate disorder with a progressive and irreversible cognition, memory, and behavior deficiency. This disease is pathologically characterized by the amyloid beta (Aβ) protein neutric plaques and fibrillary tangles composed of hyperphosphorylated tau protein. Thus, misfolding, aggregation and propagation of Aβ and tau in the brain of AD patient is considered as the main pathological cause. Currently, the clinical approved drugs for AD treatment are mainly acetylcholinerase inhibitors and N-methyl-d-aspartate receptor antagonists. Combined method of in silico and in vitro which is cost-effective and time-saved has already been used in the exploration of AD therapy. New candidate drugs discussed in this review are mainly targeting the pathological proteins of Aβ and tau. The road of new drug discovery and development is full of opportunities and challenges while great and joint efforts are still needed. PMID: 29086699 [PubMed - as supplied by publisher]
Source: Current Neuropharmacology - Category: Drugs & Pharmacology Authors: Tags: Curr Neuropharmacol Source Type: research